Alicia Olivo is the Executive Vice President, General Counsel, and Head of Business Development at NeoGenomics, Inc., a leading provider of cancer genetics diagnostic testing and global contract research services. In this multifaceted role, she oversees all legal, compliance, and risk management functions while driving strategic business development efforts, including mergers and acquisitions, partnerships, and commercial growth initiatives. Olivo's leadership has been instrumental in supporting NeoGenomics' expansion in precision oncology, ensuring robust regulatory compliance amid evolving healthcare landscapes, and positioning the company for sustained innovation and market leadership. With more than 20 years of experience in the diagnostics and healthcare industries, Olivo brings a wealth of expertise from senior roles at prominent organizations. Prior to joining NeoGenomics in 2021, she served as Senior Vice President, General Counsel, and Corporate Secretary at Inovalon, Inc., where she managed global legal operations and played a key role in the company's $7.3 billion acquisition by Nordic Capital. Her earlier career includes serving as General Counsel at Genomic Health, Inc., and holding progressive leadership positions at Laboratory Corporation of America Holdings (LabCorp), where she advised on complex transactions, intellectual property matters, and FDA regulatory strategies. A graduate of the University of Pennsylvania with a B.A. in English and Fordham University School of Law with a J.D., Olivo is recognized for her strategic acumen and ability to bridge legal rigor with business objectives. Her achievements include facilitating high-stakes deals and fostering compliant growth in fast-paced biotech environments, making her an invaluable asset to NeoGenomics' mission of advancing cancer care through cutting-edge diagnostics.